Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 225 for “"Leukaemia"”.

  1. The early stages of leukaemia

    … has been a growing literature on the subject of leukaemia in its earlier stages, and it is becoming apparent that conditions formerly thought to be separate entities, are actually unusual manifestations of a well recognised type. Thus the classification and nomenclature tends to become …

    edinburgh Repository record for The early stages of leukaemia (opens in a new tab)

  2. Proteasome inhibition in chronic myeloid leukaemia

    CML is treated effectively with TKI, however two key problems remain - the insensitivity of CM HSC to TKI and the emergence of TKI-resistant BCR-ABL mutations. BCR-ABL activity is associated with increased proteasome activity and PI are cytotoxic against CML cell lines. We demonstrate that …

    glasgow Repository record for Proteasome inhibition in chronic myeloid leukaemia (opens in a new tab)

  3. Study of the chemotherapy of leukaemia

    … disease one hundred years ago, the treatment of leukaemia has passed through two main phases. During the first fifty years treatment was by chemical agents. A ,large variety underwent clinical trial and some were found to temporarily influence the leukaemic process. Unfortunately many were highly …

    edinburgh Repository record for Study of the chemotherapy of leukaemia (opens in a new tab)

  4. Immunological markers in hairy-cell leukaemia

    … a previously unrecognised marker in hairy-cell leukaemia (HCL), a receptor for IgM. The rosette method used to reveal this receptor, and the conditions affecting rosette formation are described. A kinetic study of this receptor is used to provide a measure of membrane turnover in HCL. The …

    cambridge Repository record for Immunological markers in hairy-cell leukaemia (opens in a new tab)

  5. Polarised secretion of leukaemia inhibitory factor

    Leukaemia inhibitory factor (LIF) is a cytokine that is active on a wide variety of cells. Multiple LIF transcripts have been described. The transcripts LIF-D and LIF-M encode different signal peptides, which in mouse have been associated with differential localisation of the mature protein. LIF-D …

    aston Repository record for Polarised secretion of leukaemia inhibitory factor (opens in a new tab)

  6. Characterisation of the leukaemia-associated ETO homologues

    … might have implications for the onset of leukaemia, since it opens up for an AML1-ETO mediated disturbance of ETO homologue function as well as a regulation of AML1-ETO function by the ETO homologues. Examination of the expression patterns of ETO homologues in hematopoetic cells show that …

    lund Repository record for Characterisation of the leukaemia-associated ETO homologues (opens in a new tab)

  7. Antioxidant pathways and human leukaemia chemotherapeutic sensitivity

    … has effectively eradicated chronic myeloid leukaemia (CML) morbidity. However, acute myeloid leukaemia (AML) remains essentially incurable for the vast majority of patients. The current gold-standard treatment for AML has remained relatively unchanged for decades, consisting of the …

    east-anglia Repository record for Antioxidant pathways and human leukaemia chemotherapeutic sensitivity (opens in a new tab)

  8. Characterisation of genetic complexity in chronic lymphocytic leukaemia

    Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia in the Western world, characterised by the accumulation of mature B-cells. The disease has a heterogeneous course whereby some patients do not require treatment for several years while others follow a more aggressive disease …

    oxford-brookes Repository record for Characterisation of genetic complexity in chronic lymphocytic leukaemia (opens in a new tab)

  9. Functional role of ZAP70 in Chronic Lymphocytic Leukaemia

    Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia. It is common in older people and rare in people under 40. CLL is characterised by the accumulation of monoclonal CD5+CD23+ B lymphocytes in the blood, bone marrow and secondary lymphatic tissues. There are 2 main subtypes of …

    cambridge Repository record for Functional role of ZAP70 in Chronic Lymphocytic Leukaemia (opens in a new tab)

  10. Acquired abnormalities of chromosome 21 in acute lymphoblastic leukaemia

    … abnormality in<br/>childhood acute lymphoblastic leukaemia (ALL). It is defined by multiple copies<br/>of the RUNX1 gene, as seen by fluorescence in situ hybridisation (FISH), localised<br/>to a single abnormal duplicated chromosome 21 [dup(21)]. The morphological<br/>form of this chromosome is …

    soton Repository record for Acquired abnormalities of chromosome 21 in acute lymphoblastic leukaemia (opens in a new tab)

  11. In Our Blood: Mapping Narrative Enactments of Leukaemia Online

    … considered incurable, chronic lymphocytic leukaemia (CLL) presents with variable progression outcomes from indolent, through actively progressive, to terminal in some cases. Diagnosed with CLL myself, and having learned much of what I know about my disease online, this virtual ethnography …

    arts-london Repository record for In Our Blood: Mapping Narrative Enactments of Leukaemia Online (opens in a new tab)

  12. The Mechanisms of HOXA9-mediated Acute Myeloid Leukaemia Maintenance

    Acute myeloid leukaemia (AML) is an aggressive haematological malignancy, which, despite recent advances in treatment, results in only 50% long-term survival for the younger and lower than 10% for the older patients. Understanding the molecular mechanisms underlying leukaemogenesis and leukaemia

    cambridge Repository record for The Mechanisms of HOXA9-mediated Acute Myeloid Leukaemia Maintenance (opens in a new tab)

  13. MANIPULATING CELL STATES FOR LEUKAEMIA DIFFERENTIATION THERAPY USING NETWORK PHARMACOLOGY

    Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer which is characterized by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. In this proof-of-concept study, we demonstrate a novel utility of the MOGRIFY® algorithm in …

    nus Repository record for MANIPULATING CELL STATES FOR LEUKAEMIA DIFFERENTIATION THERAPY USING NETWORK PHARMACOLOGY (opens in a new tab)

  14. Biology of adult human normal and leukaemia CD133+ stem cells

    … stem cells; and evaluated the anti-acute myeloid leukaemia (AML) effect of 5 novel synthetic ajoene compounds using drug-resistant AML cell line for overcoming drug resistance in elderly AML patients. A novel serum-free culture system for inducing neural differentiation of human adult bone marrow …

    cent-lancashire Repository record for Biology of adult human normal and leukaemia CD133+ stem cells (opens in a new tab)

  15. Defining the Epigenetic Evolutionary Dynamics that Precede Acute Myeloid Leukaemia

    … of somatic driver mutations. Acute Myeloid Leukaemia (AML) is a good model system with which to address these questions. As well as the ease of sampling blood, mutations in epigenetic modifiers are some of the earliest and most common driver events in AML. In this work, we used peripheral …

    cambridge Repository record for Defining the Epigenetic Evolutionary Dynamics that Precede Acute Myeloid Leukaemia (opens in a new tab)

  16. The role of non-genetic variability in Acute Myeloid Leukaemia

    Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells with a dismal survival. It has a strong reliance on epigenetic and transcriptional factors for disease progression. Accordingly, my lab has previously identified KAT2A, a histone acetyl-transferase, …

    cambridge Repository record for The role of non-genetic variability in Acute Myeloid Leukaemia (opens in a new tab)

  17. Long-term effects of imatinib on cognition in chronic myeloid leukaemia

    … as a first line treatment for chronic myeloid leukaemia (CML) in the chronic, accelerated, and blastic phases. The survival advantage demonstrated by this target kinase inhibitor has meant that patients are now treated with this agent on a long-term basis. There is a growing literature on the …

    vu-aus Repository record for Long-term effects of imatinib on cognition in chronic myeloid leukaemia (opens in a new tab)

  18. The analysis of Bcr-Abl—Nox signalling in chronic myeloid leukaemia

    Chronic Myeloid Leukaemia (CML) is a myeloproliferative disorder characterised by increased proliferation of haematopoietic stem cells. CML results following generation of the chimeric protein Bcr-Abl, a constitutively active tyrosine kinase which induces oncogenesis in part by promoting increased …

    cork Repository record for The analysis of Bcr-Abl—Nox signalling in chronic myeloid leukaemia (opens in a new tab)

  19. Molecular Characterisation and Therapeutic Targeting of NPM1-mutant Acute Myeloid Leukaemia

    … the NPM1 gene are found in 30% of acute myeloid leukaemia (AML) cases. Despite their prevalence, the molecular consequences of NPM1 mutations (NPM1c) are incompletely understood and this hinders progress in designing effective therapeutic strategies. This thesis describes my work to characterise …

    cambridge Repository record for Molecular Characterisation and Therapeutic Targeting of NPM1-mutant Acute Myeloid Leukaemia (opens in a new tab)

Page 1 of 12